In vitro activity of fluoroquinolones against erythromycin-susceptible and -resistant Bordetella pertussis [4]

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 742-743

  Bourgeois, Nadege ^a,b   Ghnassia, Jean Claude ^a   Doucet Populaire, Florence ^a,b  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bordetella pertussis; Erythromycin; Gatifloxacin; Quinolones

Indexed keywords

CIPROFLOXACIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; PERTUSSIS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; COUGHING; DIAGNOSTIC ACCURACY; HUMAN; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERTUSSIS;

ANTI-INFECTIVE AGENTS; BORDETELLA PERTUSSIS; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FLUOROQUINOLONES; HUMANS; WHOOPING COUGH;

EID: 0037342241     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg145     Document Type: Letter

References (8)

1. Centers for Disease Control and Prevention. (2002). Pertussis-United States 1997-2000. Morbidity and Mortality Weekly Report 51, 73-6.
2. Bourgeois, N., Foucaud, P., Berardi-Grassias, L., Ghnassia, J. C. & Doucet-Populaire, F. (2002). Epidemiological and clinical characteristics of pertussis in French children. In Program and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 2002. Abstract G-1476, p. 255. American Society for Microbiology, Washington, DC, USA.
3. Fung-Tomc, J., Minassian, B., Kolek, B., Washo, T., Huczko, E. & Bonner, D. (2000). In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. Journal of Antimicrobial Chemotherapy 45, 437-46.
4. Wilson, K., Cassiday, P., Bartkus, J., Doucet-Populaire, F. & Sanden, G. (2001). Characterization of a new erythromycin resistant Bordetella pertussis phentotype. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract C1-1818, p. 102. American Society for Microbiology, Washington, DC, USA.
5. Korgenski, E. K. & Daly, J. A. (1997). Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States. Journal of Clinical Microbiology 35, 2989-91.
6. Gordon, K. A., Fusco, J., Biedenbach, D. J., Pfaller, M. A. & Jones, R. N. (2001). Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy 45, 3599-600.
7. Hoppe, J. E., Rahimi-Galougahi, A. & Seibert, G. (1996). In-vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, D-ofloxacin, ofloxacin and ciprofloxacin), cefpirome, and meropenem. Antimicrobial Agents and Chemotherapy 40, 807-8.
8. Honeybourne, D., Banerjee, D., Andrews, J. & Wise, R. (2001). Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy 48, 63-6.